Verily Life Sciences

Syllable is a developer of a text and voice-based platform designed to enhance communication between healthcare providers and patients. By leveraging artificial intelligence, the platform facilitates interactions regarding primary care, specialty referrals, vaccinations, and general practice information. This technology enables patients to access healthcare information and guidance beyond traditional clinical settings, improving overall communication and patient engagement in their healthcare journeys.

EQRx operates as a biotechnology company, focused on re-engineering the process from drug discovery to patient delivery with the goal of offering a market-based solution for the rising cost of medicines. By bringing together stakeholders from across the healthcare system and utilizing the latest advances in science and technology, the company seeks to discover, develop and deliver high-quality, patent-protected medicines more efficiently and cost-effectively than ever before. The company was founded in 2019 and is based in Cambridge, Massachusetts, United States.

Culture Biosciences, founded in 2016 and headquartered in San Francisco, California, specializes in developing automated bioreactors and tools for fermentation. The company provides a digital bio-manufacturing platform that allows biotech companies to optimize their manufacturing processes, enabling them to bring products to market more efficiently. By utilizing robotic sample handling and cloud-based data monitoring and analysis, Culture Biosciences helps scientists run, monitor, and analyze bioreactors more quickly than traditional methods. This innovative approach supports the biotechnology sector in enhancing productivity and streamlining workflows.

The SignalPath platform is the first of its kind to be built by researchers, for researchers. We provide our breakthrough software to clinical research sites, with the goal of dramatically improving the ease and efficiency of trial execution across all of the trials they are engaged in. Our purpose-built platform is designed to be used at the point of care, enabling clinical research teams to focus on their patients while achieving their research goals.

Genalyte, Inc. is a clinical and diagnostic life science company based in San Diego, California, specializing in rapid diagnostic testing solutions. Founded in 2007, Genalyte has developed an innovative technology platform that utilizes silicon photonic biosensors to quantify biomolecular interactions, such as those between antibodies and proteins. This platform, known as the Maverick, allows for the direct measurement of protein binding and nucleic acid hybridization. Genalyte's technology is employed by healthcare providers, pharmaceutical companies, and academic researchers to monitor autoimmune diseases, screen for cancer biomarkers, detect anti-drug antibodies, and test for infectious agents, including Ebola. The company aims to enhance patient care by enabling rapid diagnostics, with tests typically completed in under thirty minutes, and providing mobile laboratory solutions for real-time diagnostics.

Culture Biosciences, founded in 2016 and headquartered in San Francisco, California, specializes in developing automated bioreactors and tools for fermentation. The company provides a digital bio-manufacturing platform that allows biotech companies to optimize their manufacturing processes, enabling them to bring products to market more efficiently. By utilizing robotic sample handling and cloud-based data monitoring and analysis, Culture Biosciences helps scientists run, monitor, and analyze bioreactors more quickly than traditional methods. This innovative approach supports the biotechnology sector in enhancing productivity and streamlining workflows.

Mammoth Biosciences, Inc. is a biotechnology company based in South San Francisco, California, founded in 2017. It specializes in developing advanced CRISPR solutions, including its proprietary DETECTR technology, which allows for the detection of specific nucleic acids in samples, aiding in diagnostics for various conditions such as bacterial infections, cancer, and viral infections. The company focuses on democratizing disease detection through accessible point-of-care tests that can simultaneously identify multiple health issues. Additionally, Mammoth offers CRISPR-Cas systems for genome editing, targeting therapeutic applications in immuno-oncology, autoimmune diseases, and liver diseases. Its innovative solutions are utilized across diverse sectors, including healthcare, agriculture, environmental monitoring, and biodefense. Co-founded by CRISPR pioneer Jennifer Doudna, Mammoth Biosciences is supported by notable institutional and individual investors, reflecting its commitment to harnessing CRISPR technology for significant advancements in life sciences.

Freenome, Inc., is an artificial intelligence (AI) genomics biotech company. The company develops and provides a medical arti?cial intelligence platform for early detection of cancer. It develops blood tests for early-cancer screening and treatment selection. The company also provides clinical research services. Freenome, Inc. was founded in 2014 and is based in South San Francisco, California.

Culture Biosciences, founded in 2016 and headquartered in San Francisco, California, specializes in developing automated bioreactors and tools for fermentation. The company provides a digital bio-manufacturing platform that allows biotech companies to optimize their manufacturing processes, enabling them to bring products to market more efficiently. By utilizing robotic sample handling and cloud-based data monitoring and analysis, Culture Biosciences helps scientists run, monitor, and analyze bioreactors more quickly than traditional methods. This innovative approach supports the biotechnology sector in enhancing productivity and streamlining workflows.

Ciitizen Corporation operates a digital healthcare platform that empowers patients to collect, organize, and share their personal health information, including genomic data, lab results, and advanced directives. Founded in 2017 and based in Palo Alto, California, Ciitizen aims to provide individuals with comprehensive control over their health data, facilitating seamless sharing with caregivers, researchers, and other relevant parties. The platform addresses the limitations of existing health information systems, which often provide only minimal data and require extensive manual efforts to extract insights. By normalizing unstructured health information into actionable visualizations, Ciitizen enhances the ability of patients, caregivers, and clinicians to access and utilize vital health insights efficiently. The company is led by CEO Anil Sethi and is supported by notable investors, including Andreessen Horowitz and Verily, positioning it as a key player in the evolving landscape of patient-centered healthcare data management.

Cortexyme, Inc. is a clinical stage biopharmaceutical company based in South San Francisco, California, focused on developing therapeutics for Alzheimer's disease and other neurodegenerative disorders. The company's lead drug candidate, COR388, is an orally administered small molecule designed to inhibit gingipain, which is linked to neurodegeneration. Currently in Phase II/III clinical trials, COR388 targets patients with mild to moderate Alzheimer's disease. Cortexyme's research is grounded in a novel theory linking a specific, undisclosed pathogen to the progression of neurodegenerative conditions, a hypothesis supported by various animal model studies. The company was founded in 2012 and continues to advance its therapeutic candidates through preclinical and clinical development phases.

Insitro, Inc. is a data-driven drug discovery and development company based in South San Francisco, California, founded in 2018. The company utilizes machine learning and high-throughput biology to transform the traditional processes of drug discovery and delivery. By generating extensive functional genomic datasets and aligning them with patient data through innovative machine learning techniques, Insitro builds predictive models that aim to address critical challenges in pharmaceutical research and development. These models facilitate accelerated target selection and the design of effective therapeutics, ultimately enhancing the efficiency of drug development and informing clinical strategies. The focus of Insitro's work includes the treatment of nonalcoholic steatohepatitis (NASH), showcasing its commitment to addressing significant health issues through advanced technology.

Oscar Health is a health insurance company that provides individual and family plans, Medicare Advantage, and small group products. Founded in 2012 and headquartered in New York, Oscar Health operates in several states, including New York, Texas, California, New Jersey, Ohio, and Tennessee. The company aims to enhance the healthcare experience by utilizing technology, design, and data to create user-friendly services. Its platform includes a software application that helps users find doctors based on location and ratings. Oscar Health primarily serves individuals and families who do not receive health insurance from their employers.

Freenome, Inc., is an artificial intelligence (AI) genomics biotech company. The company develops and provides a medical arti?cial intelligence platform for early detection of cancer. It develops blood tests for early-cancer screening and treatment selection. The company also provides clinical research services. Freenome, Inc. was founded in 2014 and is based in South San Francisco, California.

Onduo is a digital healthcare company that uses data to help people with diabetes live their best life.